Bison Wealth LLC Has $398,000 Stake in Bristol-Myers Squibb (NYSE:BMY)

Bison Wealth LLC grew its position in Bristol-Myers Squibb (NYSE:BMY) by 21.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,749 shares of the biopharmaceutical company’s stock after purchasing an additional 1,381 shares during the period. Bison Wealth LLC’s holdings in Bristol-Myers Squibb were worth $398,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BMY. Dakota Wealth Management bought a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $332,000. Covestor Ltd raised its holdings in Bristol-Myers Squibb by 111.5% during the first quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 1,082 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Bristol-Myers Squibb by 53.2% during the first quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock worth $12,075,000 after acquiring an additional 57,444 shares in the last quarter. Ergoteles LLC bought a new stake in Bristol-Myers Squibb during the first quarter worth about $1,997,000. Finally, Mackenzie Financial Corp raised its holdings in Bristol-Myers Squibb by 25.1% during the first quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock worth $24,725,000 after acquiring an additional 68,018 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Down 0.5 %

Shares of BMY opened at $48.27 on Wednesday. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93. The stock has a market capitalization of $97.83 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.78 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The stock has a fifty day moving average of $51.27 and a 200-day moving average of $51.62.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.82 EPS. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 5.41 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.97%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BMY shares. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.